Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Quantitative Strategy for Pooling COVID-19 Tests Could Detect Outbreaks Early

By HospiMedica International staff writers
Posted on 09 Mar 2021
Scientists have developed a new model to evaluate the performance of a group testing strategy for the SARS-CoV-2 virus, which involves pooling samples from multiple individuals in order to conduct a single RT-PCR test on the whole group.

The theoretical study by scientists at Université Grenoble Alpes (Grenoble, France) accounts for both dilution effect and the detection limits of the RT-PCR test, in an effort to assess the number of potential false negatives based on pooled sample size, to optimize group size thereby minimizing epidemic risk, and finally to more accurately determine the number of contaminated individuals within a given population.

The principle of group testing is simple mathematically speaking: rather than test one hundred samples (one per individual), they can be pooled into ten groups of ten, with only one test for each group. More...
If the test result for a group is positive, then at least one of the group’s samples contains the infectious agent. Conversely, a negative result should, in principle, indicate that none of the combined samples contains the infectious agent. Sample pooling method can reduce the cost can accelerate screening campaign, yet pooling can result in a false positive result whenever mixing samples involves a too large dilution - namely when the quantity of the virus in the tested sample falls below the test’s level of detection.

To assess the efficiency of screening based on a group testing strategy, the researchers who are members of the MODCOV19 platform have developed a mathematical model that estimates this dilution effect based on sample group size. Their model can quantify the reduction of sensitivity for tests, hence the capacity of tests with larger or smaller groups to detect the presence of a contagious individual. Unlike methods that try to minimize the number of tests needed to establish an individual diagnostic for the contaminated individual or individuals, the model’s central aim is to help optimize a collective screening strategy: how best to optimize group size in order to detect a maximum number of individuals all while limiting the risk of false negatives?

The researchers also present an accurate method for measuring the proportion of individuals infected in the tested population (known as prevalence) which can guide the application of preventive measures against epidemic risk. According to their study, group testing is of particular interest because it can quickly and regularly evaluate the presence of SARS-COV-2 within “closed” communities (such as nursing homes or university residences).

Related Links:
Université Grenoble Alpes


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.